On Friday, Protagonist Therapeutics received an upgrade to its Relative Strength (RS) Rating, from 68 to 76.
IBD's unique RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating of at least 80 in the early stages of their moves. See if Protagonist Therapeutics can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Protagonist Therapeutics is building a consolidation with a 48.89 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Earnings grew 350% last quarter, up from 0% in the prior report. Revenue also increased, from -100% to 184%.
Protagonist Therapeutics earns the No. 5 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
